Nicotine protects rat brain mitochondria against experimental injuries

Neuropharmacology

Volumn 44, Issue 5, 2003, Pages 642-652

  Cormier, A ^a   Morin, C ^a   Zini, R ^a   Tillement, J P ^a   Lagrue, G ^b  

^a FACULTÉ DE MÉDECINE   (France)

^b Hopital Albert Chenevier   (France)

Author keywords

Anisotropy; Anoxia reoxygenation; Mitochondria; Nicotine; Parkinson's disease; Respiratory control ratio; Superoxide anions generation

Indexed keywords

NICOTINE; ROTENONE; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANISOTROPY; ANOXIA; ARTICLE; BRAIN INJURY; BRAIN MITOCHONDRION; CELL DAMAGE; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VITRO STUDY; MALE; MITOCHONDRIAL RESPIRATION; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; REOXYGENATION;

EID: 0037382337     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00041-8     Document Type: Article

References (45)

1. Allen K.L., Busza A.L., Proctor E., King M.D., Williams S.R. Studies of cerebral blood flow and energy metabolism using hydrogen clearance and 32P NMR spectroscopy. NMR in Biomedicine. 6:1993;181-186.
2. Beal M.F. Aging, energy and oxidative stress in neurodegenerative diseases. Annals of Neurology. 38:1995;357-366.
3. Beal M.F., Ferrante R.J., Henshaw R., Matthews R.T., Chan P.H., Kowall N.W., et al. 3-nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. Journal of Neurochemistry. 65:1995;919-922.
4. Belluardo N., Blum M., Mudo G., Andbjer B., Fuxe K. Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat. Neuroscience. 83:1998;723-740.
5. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience. 12:2000;1301-1306.
6. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., et al. Chronic mitochondrial energy impairment produced selective striatal degeneration and abnormal choreiform movements in primates. Proceedings of the National Academy of Sciences USA. 92:1995;7105-7109.
7. Cassarino D.S., Bennett J.P. Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Research Review. 29:1999;1-25.
8. Chandrasekaran K., Giordano T., Brady D.R., Stoll J., Martin L.J., Rapoport S.I. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Molecular Brain Research. 24:1994;1124-1129.
9. Cormier A., Morin C., Zini R., Tillement J.P., Lagrue G. In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. Brain Research. 900:2001;72-79.
10. Crooks P.A., Li M., Dwoskin L.P. Metabolites of nicotine in rat brain after peripheral nicotine administration. Cotinine, nornicotine, and norcotinine. Drug Metabolism and Disposition. 25:1997;47-54.
11. Davey G.P., Clark J.B. Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. Journal of Neurochemistry. 66:1996;1617-1624.
12. Davis J.N., Hunnicutt E.J., Chisholm J.C. A mitochondrial bottleneck hypothesis of Alzheimer's disease. Molecular Medicine Today. 1:1995;240-247.
13. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agrid F., Agrid Y., Lees A., et al. Basal lipid peroxidation is increased in Parkinson's disease. Journal of Neurochemistry. 52:1989;381-389.
14. Du G., Willet K., Mouithys-Mickalad A., Sluse-Goffart C., Droy-Lefaix M.T., Sluse F.E. EGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxygenation. Free Radical Biology and Medicine. 27:1999;596-604.
15. Fagerstrom K.O., Pomerleau O., Giordani B., Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berlin). 116:1994;117-119.
16. Fiskum G., Murphy A.N., Beal M.F. Mitochondria in neurodegeneration: acute ishemia and chronic neurodegenerative diseases. Journal of Cerebral Blood Flow Metabolism. 19:1999;351-369.
17. Fratiglioni L., Wang H.X. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behavioural Brain Research. 113:2000;117-120.
18. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Scharpira A.H.V. Mitochondrial defect in Huntington's disease caudate nucleus. Annals in Neurology. 39:1996;385-389.
19. Hirano A. Cytopathology in amyotrophic lateral sclerosis. Advances in Neurology. 56:1991;91-101.
20. Ishikawa A., Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. Journal of Neurological Sciences. 117:1993;28-32.
21. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Molecular Neurobiology. 15:1997;193-222.
22. Linert W., Bridge M.H., Huber M., Bjugstad K.B., Grossman S., Arendash G.W. In vitro and in vivo studies investigating possible antioxidant actions for nicotine: relevance to Parkinson's and Alzheimer's diseases. Biochimica et Biophysica Acta. 1454:1999;143-152.
23. Marklund S.L., Westman N.G., Lundgren E., Roos G. Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Research. 42:1982;1955-1961.
24. Martilla R.J., Roytta M., Lorentz H., Rinne U.K. Oxygen toxicity protecting enzymes in the human brain. Journal of Neural Transmission. 74:1988;87-95.
25. McCord J.M., Fridovich I. Superoxide dismutase. An enzymatic function for erythrocuprein (hemocuprein). Journal of Biological Chemistry. 244:1969;6049-6055.
26. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Annals in Neurology. 36:1994;747-751.
27. Mecocci P., Beal M.F., Cecchetti R., Polidori M.C., Cherubini A., Chionne F., et al. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA and AD human brain. Molecular and Chemical Neuropathology. 31:1997;53-64.
28. Nanri M., Yamamoto J., Miyake H. Protective effect of GTS-21, anovel nicotinic receptor agonist on delayed neuronal death induced by ischemia in Gerbils. Japanese Journal of Pharmacology. 79:1998;23-29.
29. Newhouse P.A., Potter A., Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging. 11:1997;206-228.
30. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., Smith M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. Journal of Neurosciences. 19:1999;1959-1964.
31. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annual Review of Neuroscience. 22:1999;123-144.
32. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Annals of Neurology. 26:1989;719-723.
33. Parker W.D. Jr., Filley C.M., Parks J.K. Cytochrome c oxidase deficiency in Alzheimer's disease. Neurology. 40:1990;1302-1303.
34. Parker W.D., Parks J., Filley C.M., Kleinschmidt-DeMasters B.K. Electron transport chain defects in Alzheimer's disease brain. Neurology. 44:1994;1090-1096.
35. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neuroscience Letters. 33:1982;305-310.
36. Perry E., Morris C., Court J., Cheng A., Fairbairn A., McKeith I., et al. Alteration in nicotine biding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease, possible index of early neuropathology. Neuroscience. 64:1995;305-309.
37. Riederer P., Sofic E., Rausch W.D., Schmidt D., Reynold G.P., Jellinger K., Youdim M.B.H. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. Journal of Neurochemistry. 52:1989;515-520.
38. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature. 362:1993;59-62.
39. Rossignol R., Malgat M., Mazat J.P., Letellier T. Threshold effect and tissue specificity. Implication for mitochondrial cytopatries. Journal of Biological Chemistry. 274:1999;33426-33432.
40. Rowell P.P., Li M. Dose-response relationship for nicotine-induced up-regulation for rat brain nicotinic receptors. Journal of Neurochemistry. 68:1997;1982-1989.
41. Simon N., Zini R., Morin C., Bree F., Tillement J.P. Prednisolone and azathioprine worsen the cyclosporine A-induced oxidative phosphorylation decrease of kidney mitochondria. Life Science. 61:1997;659-666.
42. Sims N.R. Rapid isolation of metabolically active mitochondria from rat brain and subregions using Percoll density gradient centrifugation. Journal of Neurochemistry. 55:1990;698-707.
43. Starkov A.A., Polster B.M., Fiskum G. Regulation of hydrogen peroxide production by brain mitochondria by calcium and Bax. Journal of Neurochemistry. 83:2002;220.
44. Ulrich Y.M., Hargreaves K.M., Flores C.M. A comparison of multiple injections versus continuous infusion of nicotine for producing up-regulation of neuronal [3H]-epibatidine binding sites. Neuropharmacology. 36:1997;1119-1125.
45. Urien S. MICROPHARM-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Pharmaceutical Research. 12:1995;1225-1230.